Its in Medical Technology

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

RESEARCH TRIANGLE PARK, N.C., July 17 /PRNewswire/ -- AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccin...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investig...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo act...

West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial

Collaboration will test remote wireless monitoring to prevent hospital readmissions for heart failure SAN DIEGO, June 24 /PRNewswire-USNewswire/ -- The West Wireless Health Institute (WWHI), one of the world's first medical research organizations dedicated to advancing health and well-being t...

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Florida's First Three-Year Neuroscience Research Doctorate Program SARASOTA, Fla., June 18 /PRNewswire/ -- Sarasota's Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laborator...

ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)

SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ -- ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate b...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY ) announced that its cartilage repair device has been highlighted in two podium presentations at the 8th World Congress of the International Cartilage Repair Society (ICRS) Meeting held in Miami, FL on May 23-26, ...

Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine

ATLANTA, May 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that Chuck Pano...

Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business

WAYNE, Pa., May 18 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO ), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmace...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Completion of enrollment keeps Company on track to report primary study results in third quarter of this year ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the second Phase II clinical trial of its trival...

Tris Pharma Announces Acceptance of Its First Two NDAs

- First ever 24 hour oral liquid sustained release formulation submitted to the FDA - Validates OralXR(TM) technology platform - eliminates the need to swallow pills by providing sustained release in liquids, chewable tablets, and films - Upon approval will provide both liquid and tablet...

AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System

REDWOOD CITY, Calif., May 5 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of its ARX-01 Sufentanil NanoTab(TM) PCA System, a proprietary drug/device combination product candidate being developed for management of acute post-operative pa...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Phase 2b clinical trials will commence this week on 30 Type 2 Diabetic volunteers. The study is intended to evaluate the safety, t...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

-Preliminary Data from This Trial to be Presented at ASCO- -First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment- TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces the signature of an ...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

New Collaboration with Leading Researchers having Clinical Experience with Antimicrobials that are Biological Basis for Aganocide Compounds EMERYVILLE, Calif., April 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ), a mid-stage biopharmaceutical company developin...

NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device

NESHER, Israel, April 21 /PRNewswire/ -- NanoVibronix, a medical device company specializing in applications that implement surface ultrasound waves, announced that its novel device has received CE approval in Europe for additional claims of wound healing. PainShield is the first hands-free, p...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinic...

Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions

BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate. "Our most recent Phase IIb study, the largest trial with an investigational medica...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of altern...

Premier Research Expands its Medical Device Operations to the United States

PHILADELPHIA, March 11 /PRNewswire/ -- Premier Research Group Limited, the international clinical services group, is pleased to announce that it has expanded their medical device operations to include full coverage in the United States. Their dedicated medical device group has been offering clinic...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

Studies Support Potential for Alzheimer's Disease and Other Neurodegenerative Diseases NEW YORK, March 3 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheim...

Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB ) today announced that an Independent Data Monitoring Committee (IDMC) has completed a planned, pre-specified safety review of interim data from the ongoing pivotal rALLy clinical trial of Marqibo(R...

Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma

EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free latanoprost formulation for glaucoma. Novagali communicated about "Ocular safety compari...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer'...

CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial

LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. Th...

Vermillion Presents Critical Data From Its OVA1 Clinical Trial

Study Presented at Society of Gynecologic Oncologists' 40th Annual Meeting - on Women's Cancer FREMONT, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, presented data from its prospective OVA1 clinical trial a...

Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation

RESEARCH TRIANGLE PARK, N.C., Jan. 26 /PRNewswire/ -- Mardil Inc., a cardiac device company with novel technology for treating mitral valve regurgitation, has successfully advanced its device to first-in-human testing, a milestone achievement for the 2-year-old company. The first patient was...

UK Must Maintain its Momentum in Stem Cell Expertise

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology. Professor Sir Christoph...

Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP

- Single Injection in Primates Containing 1,000-Times the Dosage Recommended for Humans Shows No Adverse Effects - - Half-Life and AUC Support the Potential for Weekly or Bi-Monthly Dosing Frequency - NES-ZIONA, Israel, Jan. 15 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board:...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

CORAL GABLES, Fla., Jan. 9 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, announced today that it has reached its pat...

Delcath Adds Dr. Pamela R. Contag to Its Board of Directors

NEW YORK, Dec. 17 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) today announced the appointment of Pamela R. Contag, Ph.D., to Delcath's Board of Directors. Dr. Contag is a proven corporate executive with extensive experience working with international and domestic investors....

Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests

REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, December 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its first diagnostic test, miRview(TM) squamous. Th...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009 ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc...

New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures

Studies Presented at American Epilepsy Society Annual Meeting ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracet...